Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.
Lumos Diagnostics has received a US$0.4 million payment from Hologic for reaching a Phase 1 milestone in their Development Agreement, with the revenue impacting the FY2024 financial results. The company is progressing with Phase 2, aiming to unlock an additional US$0.6 million milestone payment, as part of a larger US$4.7 million program. Lumos’s cash position has been bolstered by this achievement, as they continue to specialize in rapid point-of-care diagnostic technologies.
For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.
